Gossamer Bio
GOSS
74 hedge funds and large institutions have $813M invested in Gossamer Bio in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 11 closing their positions.
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
4% more funds holding
Funds holding: 71 → 74 (+3)
1.19% more ownership
Funds ownership: 54.49% → 55.68% (+1.2%)
5% more capital invested
Capital invested by funds: $776M → $813M (+$36.5M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.58M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.88M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.37M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.73M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.32M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.49M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$3.43M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.25M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.99M |
GOSS Hedge Fund Activity: Q2 2019 in Review
74 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2019, worth a combined $813M — up 4.7% from $776M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GOSS positions and 11 closed out — a net gain of 5 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $9.58M. The largest seller was Farallon Capital Management, cutting an estimated $5.32M.
- 74 institutional investors held Gossamer Bio (GOSS) as of Q2 2019, up from 71 in Q1 2019.
- Funds reported $813M of Gossamer Bio stock for Q2 2019, up 4.7% quarter-over-quarter.
- 16 funds opened new Gossamer Bio positions in Q2 2019 and 11 closed out, a net change of +5 holders.
- The largest Gossamer Bio buyer in Q2 2019 was BlackRock, an estimated $9.58M added.
- The largest Gossamer Bio seller in Q2 2019 was Farallon Capital Management, an estimated $5.32M sold.
Based on aggregated 13F filings for Q2 2019.